Kyverna Therapeutics (NASDAQ:KYTX) Issues Earnings Results, Misses Estimates By $0.01 EPS

Kyverna Therapeutics (NASDAQ:KYTX) released its quarterly earnings results on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.01), Zacks reports.

Kyverna Therapeutics Trading Down 5.6 %

Shares of NASDAQ:KYTX opened at $2.36 on Friday. Kyverna Therapeutics has a one year low of $2.20 and a one year high of $25.84. The business’s fifty day moving average price is $2.87 and its two-hundred day moving average price is $4.20.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Kyverna Therapeutics stock. Bank of America Corp DE increased its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 41.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,788 shares of the company’s stock after purchasing an additional 6,400 shares during the quarter. Bank of America Corp DE owned 0.05% of Kyverna Therapeutics worth $81,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.